Exposure-response analysis of rilotumumab in gastric cancer: The role of tumour MET expression

British Journal of Cancer

Volumn 112, Issue 3, 2015, Pages 429-437

  Zhu, M ^a   Tang, R ^a   Doshi, S ^a   Oliner, K S ^a   Dubey, S ^a   Jiang, Y ^a   Donehower, R C ^b   Iveson, T ^c   Loh, E Y ^a   Zhang, Y ^a  

^a AMGEN INC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

exposure response analysis; gastric cancer; MET; pharmacokinetics; rilotumumab

Indexed keywords

RILOTUMUMAB; SCATTER FACTOR RECEPTOR; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOKALEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; STOMACH NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84922141174     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.649     Document Type: Article

References (29)

1. Accornero P, Pavone LM, Baratta M (2010) The scatter factor signaling pathways as therapeutic associated target in cancer treatment. Curr Med Chem 17: 2699-2712.
2. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A, An FQ, Kamei S Iizuka H, Fujii H, Matsumoto Y (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63: 286-296.
3. Beppu K, Uchiyama A, Morisaki T, Nakamura K, Noshiro H, Matsumoto K Nakamura T, Tanaka M, Katano M (2000) Elevation of serum hepatocyte growth factor concentration in patients with gastric cancer is mediated by production from tumor tissue. Anticancer Res 20: 1263-1267.
4. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925.
5. Bruno R, Lu JF, Sun YN, Claret L (2011) A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol 51: 6-8.
6. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X Jia XC, Green L, Radinsky R, Kendall R (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66: 1721-1729.
7. Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF (2001) Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA 98: 7443-7448.
8. Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN (2012) Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer. Clin Pharmacol Ther 92: 631-634.
9. Claret L, Lu JF, Sun YN, Bruno R (2010) Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol 66: 1141-1149.
10. Dijkman B, Kooistra B, Bhandari M. Evidence-Based Surgery Working G (2009) How to work with a subgroup analysis. Can J Surg 52: 515-522.
11. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP Holscher AH, Monig SP (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19: 1477-1483.
12. Gao CF, Xie Q, Zhang YW, Su Y, Zhao P, Cao B, Furge K, Sun J, Rex K Osgood T, Coxon A, Burgess TL, Vande Woude GF (2009) Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 8: 2803-2810.
13. Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM Oliner KS, Yan L, Zhu M, Gore L (2010) Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 16: 699-710.
14. Han SU, Lee JH, Kim WH, Cho YK, Kim MW (1999) Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma. World J Surg 23: 1176-1180.
15. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A Dubey S, Oliner KS, Loh E (2014) Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 15: 1007-1018.
16. Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR Jhanwar SC, Shah MA (2011) MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev 20: 1021-1027.
17. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, Burgess TL (2007) AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 13: 6735-6742.
18. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29: 4803-4810.
19. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E Tibaldi E, Johnson BE, Salgia R (2002) Modulation of the c-Met/ hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8: 620-627.
20. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J Matsuda M, Sakaguchi T, Hirao T, Nakano H (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85: 1894-1902.
21. Nishiyama T, Sasaki T, Takaishi K, Kato M, Yaku H, Araki K, Matsuura Y Takai Y (1994) rac p21 is involved in insulin-induced membrane ruffling and rho p21 is involved in hepatocyte growth factor-and 12-Otetradecanoylphorbol-13-acetate (TPA)-induced membrane ruffling in KB cells. Mol Cell Biol 14: 2447-2456.
22. Ratain MJ, Humphrey RW, Gordon GB, Fyfe G, Adamson PC, Fleming TR Stadler WM, Berry DA, Peck CC (2008) Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer 44: 8-11.
23. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M (2004) Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand J Gastroenterol 39: 754-760.
24. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura T Miwa K, Endo Y, Yamamoto H, Watanabe H (1998) The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82: 2112-2122.
25. Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A, Toi M (1997) Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. Br J Cancer 75: 673-677.
26. Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S Grasela DM (2010) Model-based drug development: strengths weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol 50: 31S-46S.
27. Workman P (2002) Challenges of PK/PD measurements in modern drug development. Eur J Cancer 38: 2189-2193.
28. Wu CW, Li AF, Chi CW, Chung WW, Liu TY, Lui WY, PEng FK (1998) Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5: 817-822.
29. Zhu M, Doshi S, Gisleskog PO, Oliner KS, Perez Ruixo JJ, Loh E, Zhang Y (2014) Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients. J Pharm Sci 103: 328-336.